Audentes Therapeutics News Releases http://investors.audentestx.com/ Audentes Therapeutics News Releases en Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-announces-inducement-grants-under-nasdaq-5 SAN FRANCISCO , June 7, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards on June 5, 2019, Fri, 07 Jun 2019 18:00:00 -0400 Audentes Therapeutics News Releases 8741 Audentes Therapeutics Announces Changes to Senior Management Team http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-announces-changes-senior-management-team - Edward R. Conner, M.D. appointed as Senior Vice President and Chief Medical Officer - Fulvio Mavilio, Ph.D. promoted to Senior Vice President of Translational Science - Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM, Senior Vice President and Chief Medical Officer and John Gray, Ph.D. Wed, 29 May 2019 16:01:00 -0400 Audentes Therapeutics News Releases 8706 Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-participate-bank-america-merrill-lynch SAN FRANCISCO , May 8, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the Bank of Wed, 08 May 2019 08:00:00 -0400 Audentes Therapeutics News Releases 8686 Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-reports-first-quarter-2019-financial - Recently presented positive new data from ASPIRO, the Phase 1/2 study of AT132 for treatment of XLMTM - On track to submit updated ASPIRO data package with optimal dose selection to FDA in the second quarter of 2019 and to provide update on the license application submission plans for AT132 in Tue, 07 May 2019 16:01:00 -0400 Audentes Therapeutics News Releases 8671 Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-presents-new-positive-data-aspiro-phase-12 - New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2 - Significant and sustained improvements in neuromuscular function in both dose cohorts, with corresponding achievement of clinically meaningful motor Wed, 01 May 2019 14:15:00 -0400 Audentes Therapeutics News Releases 8656 Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019 http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-release-first-quarter-2019-financial SAN FRANCISCO , April 30, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its Tue, 30 Apr 2019 08:00:00 -0400 Audentes Therapeutics News Releases 8646 Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-announces-inducement-grants-under-nasdaq-4 SAN FRANCISCO , April 26, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards Fri, 26 Apr 2019 18:00:00 -0400 Audentes Therapeutics News Releases 8641 Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-announces-launch-new-state-art-internal - Facility further establishes the company's leadership in AAV manufacturing and enables the rapid advance of neuromuscular programs from preclinical development to commercialization SAN FRANCISCO , April 23, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a leading AAV-based Tue, 23 Apr 2019 08:00:00 -0400 Audentes Therapeutics News Releases 8621 Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-announces-upcoming-presentations-22nd - Oral presentation of ASPIRO results to include new data, with up to 48-weeks of follow-up for all patients in dose Cohort 1 and up to 24-weeks in the earliest patients in dose Cohort 2 - Presentation to be featured in the plenary session "Presidential Symposium & Presentation of the Top Mon, 15 Apr 2019 16:01:00 -0400 Audentes Therapeutics News Releases 8616 Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy http://investors.audentestx.com/news-releases/news-release-details/audentes-therapeutics-announces-expansion-aav-technology - Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) - Exclusive license agreement with the Research Institute at Nationwide Mon, 08 Apr 2019 07:00:00 -0400 Audentes Therapeutics News Releases 8596